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Abstract
ARID1A DEFICIENCY AS A BIOMARKER FOR SENSITIVITY TO
IONIZING RADIATION AND ATR INHIBITION IN GYNECOLOGIC
MALIGNANCIES
Jessie Y. Li, Shari Damast, MD (Department of Therapeutic Radiology, Yale
University, Yale School of Medicine, New Haven, CT), and Gloria Huang, MD
(Section of Gynecologic Oncology, Department of Obstetrics, Gynecology, and
Reproductive Sciences, Yale University, Yale School of Medicine, New Haven, CT)
Objective: ARID1A, which encodes a protein that participates in the SWI/SNF
chromatin remodeling complex, is frequently mutated in ovarian and endometrial
malignancies. The emergence of the role of ARID1A in gynecologic cancer
progression reveals potential implications for therapeutic targets. Our primary
purpose was to investigate ARID1A deficiency as a potential biomarker conferring
sensitivity to ionizing radiation and ATR inhibitors.
Methods: Paired isogenic cell lines ES2 and HCT116 were used containing wild-type
ARID1A or homozygous loss of function ARID1A mutations. Ionizing radiation doses
were delivered using Precision X-ray 320-kV orthovoltage unit at a dose rate of 2
Gy/45 seconds. Cytotoxicity assays were performed to evaluate cell survival
following various doses of ATR inhibitor AZD6738. Clonogenic survival assays were
performed with or without 50 nM of AZD6738 1 hour prior to radiation at doses of 0,
1, 2, 4, or 6 Gy. Survival curves were generated and compared using the linear
quadratic equation on GraphPad Prism. gH2AX foci formation following radiation at
5 Gy was observed using immunofluorescence (IF) and Western blot. IF images were
analyzed using ImageJ. Cell cycle distribution following radiation at 5 Gy was
performed using flow cytometry and analysis was performed using FlowJo software.
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Results: ARID1A-/- cells exhibited greater sensitivity to radiation alone compared to
ARID1A+/+ cells as measured by clonogenic survival and demonstrated a diminished
DNA damage response following radiation compared to ARID1A+/+ cells, as
measured by gH2AX foci formation by IF and Western blot. ARID1A-/- cells exhibited
an impaired G2/M cell cycle checkpoint following radiation, as exhibited by delayed
cell cycle arrest at G2/M compared to wild-type cells. ARID1A-/- cells demonstrated
sensitization to AZD6738 alone compared to wild-type cells by cytotoxicity assay.
Preliminary results suggest that ARID1A-/- cells greater sensitization to AZD6738
treatment prior to radiation compared to radiation alone. Further evaluation of
combinatorial strategies is in progress.
Conclusions: Our in vitro findings confirm that ARID1A deficiency confers
sensitivity to radiation and ATR inhibition, suggesting a biologically informed
treatment strategy for ARID1A-deficient malignancies. Further work regarding dosing
and timing of combination treatment will be explored in the future.
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Introduction
1. Introduction to SWI/SNF complexes and ARID1A
The switch/sucrose non-fermentable (SWI/SNF) complex is a chromatin
remodeling complex that modifies chromatin structure in order to alter DNA
accessibility for transcriptional and regulatory machinery. The SWI/SNF complex
accomplishes its role by using ATP hydrolysis to break DNA-histone contacts and to
mobilize nucleosomes [1]. The complex plays a significant role in DNA replication,
transcription, and repair; thus, dysfunction within the SWI/SNF pathway is a potential
epigenetic mechanism for tumorigenesis. In fact, mutations within the SWI/SNF
complex are found in an estimated 20% of all human cancers, making it one of the
most commonly mutated tumor suppressors in cancer [2, 3].
The AT-rich interacting domain-containing protein 1A gene (ARID1A)
encodes a 250-kDa protein that is a core subunit of the SWI/SNF complex.
ARID1A’s role within the SWI/SNF complex is thought to be recruitment of
transcriptional and co-regulatory complexes [4], with previous work demonstrating
ARID1A’s role in nuclear hormone-induced transcription and cell cycle regulator
expression [5-8]. Of the SWI/SNF subunit genes, ARID1A is the most frequently
mutated, and ARID1A mutations have been found in many types of malignancies,
among them ovarian cancer, endometrial cancer, renal cell carcinoma, stomach
cancer, transitional cell carcinoma of the bladder, esophageal cancers, and
hepatocellular carcinoma [9]. Mutations in ARID1A are typically either frameshift or
nonsense, resulting in gene inactivation and loss of the ARID1A protein, which is
generally detected using immunohistochemistry [1]. In a meta-analysis including
studies across all types of malignancies, ARID1A loss was associated with reduced

2
recurrence-free and cancer-specific survival [10], demonstrating that ARID1A may be
a clinically impactful target to study to improve patient prognosis.

2. ARID1A in gynecologic malignancies
ARID1A mutations occur with the highest frequency in gynecologic
malignancies and have been shown to occur within highly specific histologic
subtypes. Most strikingly, ARID1A is the most commonly mutated gene in ovarian
clear cell adenocarcinomas, an aggressive subtype of ovarian cancer that is often
refractory to treatment, and is found in approximately 50% of all clear cell cases [11,
12]. Additionally, ARID1A mutations are linked with 30% of ovarian endometrioid
adenocarcinomas; however, ARID1A mutations have not been found in the ovarian
serous subtype [11, 12]. Among endometrial cancers, ARID1A loss is found in
approximately 40% of uterine endometrioid adenocarcinomas, 25% of uterine clear
cell carcinomas, 18% of uterine serous carcinomas, and 14% of uterine
carcinosarcomas [13]. ARID1A loss more commonly occurs among endometriosisassociated cases compared to non-endometriosis-associated cases, with previous
studies suggesting that ARID1A loss occurs early in tumorigenesis, starting with
endometriosis progressing to malignancy [12, 14]. Yamamoto et al. demonstrated that
86-100% of adjacent precursor lesions to ARID1A-deficient ovarian cancer were also
found to have ARID1A loss, while distant precursor lesions in ARID1A-deficient
cancers had retained ARID1A expression. Further, adjacent precursor lesions in
ARID1A-intact cancers had retained expression [14]. However, the mechanism for
which endometriosis may lead to tumor development remains unclear.

3. Mechanisms of ARID1A as a tumor suppressor
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ARID1A-containing SWI/SNF complexes have been shown to play various
tumor suppressor roles. Here, we discuss previous work investigating the mechanisms
of ARID1A as a tumor suppressor. ARID1A is known to have both gatekeeper roles
(regulation of cell cycle, apoptosis, and cellular proliferation) and caretaker roles
(maintenance of genomic integrity).
First, ARID1A has been demonstrated to have roles in regulating cellular
proliferation. Guan et al. demonstrated that ARID1A silencing resulted in an increased
rate of cellular proliferation, while restoration of ARID1A expression suppressed
cellular proliferation and tumor growth in ovarian clear cell and uterine endometrioid
carcinoma cell lines [15]. Similar results have been shown in breast cancer, gastric
cancer, bile duct cancer, and hepatocellular carcinoma cell lines. ARID1A has also
been found to regulate expression of cell cycle genes and are thus important in cell
cycle arrest. In a pre-osteoblastic cell line model, ARID1A-depleted cells were unable
to undergo cell cycle arrest during differentiation, as the SWI/SNF complex is
essential in repressing promoters that are critical in the induction of p21, a key
regulator in cell cycle progression [5, 6]. ARID1A additionally plays a role in
transcriptional regulation of telomerase reverse transcriptase (TERT), which
maintains telomere length and can thus provide a survival advantage for tumor
development. ARID1A serves as negative regulator of TERT transcription and activity
by binding to the TERT regulatory element and promoting a repressive chromatin
structure [16].
Interestingly, ARID1A mutations in gynecologic cancers have been found to
coexist with other aberrations. One such co-existing aberration occurs in p53.
Previous work has demonstrated a direct interaction between ARID1A and p53,
supporting a role of ARID1A in regulating transcription of p53 targets, including
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CDKN1A and SMAD3. This suggests that ARID1A works in tandem with p53 by
transcriptionally activating downstream genes that prevent tumor development [15].
ARID1A mutations are also found to coexist with aberrations in the PI3K/AKT
pathway, a signaling pathway involved in cell cycle regulation. Overactivity of this
pathway inhibits apoptosis and promotes unregulated cell proliferation and growth,
promoting cancer development. Common coexisting alterations with ARID1A
mutations include loss of PTEN (inhibitor of the PI3K/AKT pathway) and activating
mutations of PIK3CA. Guan et al. showed that mice with ARID1A/PTEN double
knockouts developed tumors; however, mice with only single deletions of either gene
did not develop discernable changes [17], suggesting that ARID1A mutations alone
are not sufficient for tumorigenesis, though they work in combination with other
aberrations to initiate cancer development.
Additionally, ARID1A-containing SWI/SNF complexes appear to have roles
in facilitating DNA repair. Thus, aberrations in the SWI/SNF complex can promote
genomic instability and subsequent tumorigenesis. The specific role that ARID1A
plays in SWI/SNF-mediated DNA repair has not been fully elucidated, though it is
likely to play a large role in repair mechanisms given the high mutation frequency of
ARID1A in human malignancy. Park et al. demonstrated that inactivation of SWI/SNF
complexes resulted in defects on H2AX phosphorylation following DNA damage,
having an impact on the efficiency of DNA double strand break (DSB) repair [18].
Shen at al. showed that ARID1A is recruited to DNA DSB and plays a role in
sustaining ATR activation in response to DNA damage [19]. ARID1A has also been
found to impact DNA mismatch repair (MMR) by recruiting MMR protein MSH2 to
chromatin during DNA replication. ARID1A deficiency was found to disrupt DNA
MMR, leading to microsatellite instability and increased mutagenesis [20]. Lastly,
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SWI/SNF complexes have also been found to be involved with pyrimidine dimers
following UV damage [21] and nucleotide excision repair [22].

4. Therapeutic strategies in ARID1A deficiency
Because the majority of ARID1A mutations are inactivating, ARID1A is a
challenging therapeutic target, given current limitations in restoring tumor suppressor
function in patients. Instead, studying ARID1A as a target requires investigation of
therapeutic vulnerabilities created by the molecular consequences of ARID1A
deficiency. Many strategies rely on the concept of synthetic lethality, in which
inactivation (either by genetic or pharmacologic means) of a combination of targets
leads to cell death, though inactivation of one of the two individually does not impact
cell viability. Here, we discuss several synthetic lethal targets of current interest in the
literature.
ARID1B, another subunit in SWI/SNF complexes that is mutually exclusive
with ARID1A, has been identified as a potential vulnerability in ARID1A-deficient
cells. Because ARID1A plays the dominant role in modulating chromatin accessibility
for enhancers, ARID1B-containing SWI/SNF complexes only contribute significantly
in the setting of ARID1A deficiency. However, ARID1B is only able to act at a certain
subset of enhancers [23, 24]. Thus, inhibition of ARID1B represents an opportunity to
target the remaining activity of the SWI/SNF complex provided by ARID1B in the
setting of ARID1A deficiency.
As discussed previously, ARID1A mutations often co-occur with loss of PTEN
or activating mutations of PIK3CA, leading to overactivation of the PI3K/AKT
pathway and increased cellular proliferation. PI3K/AKT inhibitors are able to disrupt
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this interdependency, and these inhibitors have been found to have increased
sensitivity within ARID1A-depleted cells [25].
Several additional potential targets emerge from ARID1A’s role in DNA
repair. First, as a consequence of ARID1A’s participation in DNA mismatch repair,
ARID1A-deficient cells have increased microsatellite instability and subsequent
elevation in mutation load, tumor-infiltrating lymphocytes, and PD-L1 expression. As
a result, ARID1A-deficient tumors were found to be more sensitive to immune
checkpoint blockade, with anti-PD-L1 antibody reducing tumor burden and
prolonging survival of mice with ARID1A-deficient tumors but having minimal effect
on ARID1A wild-type tumors [20]. Further, because ARID1A has also previously
found to have a role in DNA DSB repair, PARP and ATR inhibitors have been
investigated as potential synthetic lethal targets for ARID1A-mutant cancers. PARP
inhibitors, which disrupt ability to repair single-strand DNA repair and eventually
force DSBs to form, are effective when DSB repair pathways are impacted. PARP
inhibitors are most widely known for their efficacy in BRCA1 and BRCA2-mutant
cancers, though have also been found to sensitize ARID1A-deficient cancer cells as
well [19]. Further, Park et al. demonstrated efficacy of combination treatment with
radiation and PARP inhibitors in ARID1A-deficient cells [26]. Clinical ATR inhibitors
have also been investigated and found to sensitize ARID1A-deficient cancer cells by
triggering premature mitotic entry and subsequent apoptosis [27].
Other potential treatment strategies that have been investigated include
inhibition of EZH2, inhibition of HDAC6, and kinase inhibitor dasatinib. EZH2 is a
subunit of the Polycomb group complex, which typically acts to compact chromatin.
EZH2 inhibitors have shown some efficacy in ARID1A-deficient tumors, likely
because EZH2 inhibitors eliminate the activity of Polycomb complexes that is
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facilitated by aberrations in the SWI/SNF complex [28]. Inhibitors of HDAC6 have
also been seen to have some efficacy in ARID1A-mutant ovarian cancers. HDAC6’s
function includes regulation of protein trafficking, protein degradation, and cell
migration. HDAC6 is typically transcriptionally repressed by SWI/SNF complexes
and thus aberrations in SWI/SNF result in de-repression of HDAC6 activity [29].
Lastly, Miller et al. used high-throughput cell-based drug screens to identify dasatinib
as a synthetic lethal agent with ARID1A deficiency, as ARID1A-mutant ovarian clear
cell carcinoma cells were found to be addicted to dasatinib target YES1 [30].

5. Purpose of this work
This work is most interested in the therapeutic vulnerabilities generated by
ARID1A’s role in DNA repair. Specifically, data demonstrating ARID1A’s
participation in facilitating DNA DSB repair suggests that ARID1A mutant tumors
may be more sensitive to ionizing radiation, which directly induces DNA DSBs.
Furthermore, the molecular consequences of ARID1A deficiency for the response of
gynecologic cancers to ionizing radiation remain unclear. Additionally, to our
knowledge, there is no data investigating ATR blockade sensitization in ARID1Adeficient cells prior to radiation therapy. A previous study found that ATR blockade
in ARID1A-mutant tumors triggers premature mitotic entry [27], raising the question
of whether ATR inhibition may further sensitize tumors after radiation-induced DNA
damage given an increased reliance on ATR checkpoint activity. This work will thus
aim to further investigate the therapeutic vulnerabilities sensitizing ARID1A-depleted
cells to radiation therapy and ATR blockade in an ovarian clear cell carcinoma cell
model, with the eventual goal of evaluating a combination therapy of radiation and
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ATR inhibition. We believe that this work will have clinical implications in
investigating novel therapeutic strategies for ARID1A-mutant malignancies.

Statement of Purpose
The specific aims of our work is outlined below:
-

To investigate sensitivity of ARID1A-deficient cells to ionizing radiation in an
ovarian clear cell carcinoma cell line model

-

To investigate the DNA damage response in ARID1A-deficient cells following
ionizing radiation

-

To confirm sensitivity of ARID1A-deficient cells to ATR blockade in an
ovarian clear cell carcinoma cell line model

-

To investigate sensitivity of ARID1A-deficient cells to ionizing radiation in the
setting of ATR blockade.

Methods
Contributions
JL independently completed all experiments detailed in this work, unless
otherwise noted below. JL was responsible for maintaining cell cultures relevant to
her work. JL was trained as a user of the Precision X-ray 320-kV orthovoltage unit for
cell irradiation. JL was closely involved in the development of the project idea, as
well as selecting, modifying, and troubleshooting experimental strategies and
techniques. JL completed all data analysis independently. JL was also responsible for
the completion of this thesis in its entirety.
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ZL was responsible for generating the ARID1A-knockout cell lines. In
addition, he performed the AZD6758 cytotoxicity assays.

Methods Description
Cell lines
Cell lines ES2 and HCT116 were used in this study. ARID1A-knockout
HCT116 (homozygous truncating mutations Q456*/Q456*) and ARID1A wild-type
HCT116 colorectal cancer lines were obtained from Horizon Discovery. ARID1A
knockouts were generated in ovarian cancer cell line ES2 using the CRISPR-Cas9
system as described in Ran et al. [31] The CRPSIR/Cas9 vector used was
pSpCas9(BB)-2A-Puro (PX459) V2.0 (ID: 62988) and was obtained from Addgene.
The target sequence (5′-CACCGAGGGAAGCGCTGCTGGGAAT-3′) was inserted
into the cloning site of the PX459 vector. The cloned plasmid was then transfected
into ES2 cells using Lipofectamine 3000, and cells were selected using puromycin
(1ug/mL). Knockout clones were confirmed by Western blot and confirmed by
Sanger sequencing.

Clonogenic Survival Assay
Cells were harvested using trypsinization and were resuspended in medium.
To count the cells, a small sample of cells were mixed in equal parts with 0.4%
Trypan Blue solution and 10uL was pipetted into a Countess chamber slide and
inserted into the Countess 3 Automated Cell Counter. Cells diluted to the desired
seeding concentration (2000, 1000, 500, or 250 cells per mL). Two mL of medium
were plated in triplicate wells using 6-well plates. Cells were allowed to adhere to the
plate overnight. Cells were treated with the experimental condition. For radiation
treatment, ionizing radiation doses were delivered at doses of 0.5, 1, 2, 4, and 6 Gy
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using the Precision X-ray 320-kV orthovoltage unit at a dose rate of 2Gy/45 seconds.
For ATR inhibitor treatment, a stock solution of 20mM AZD6738 was diluted to the
desired concentration (25-1000 nM). For combination treatment, cells were treated
with AZD6738 1 hour prior to radiation treatment, and the fresh medium was added
24 hours after radiation. Cells were incubated for 7 days. The medium was then
removed and cells were stained with 0.5% crystal violet solution in 20% methanol.
Plating efficiency (PE) in the untreated control condition was determined with the
following equation: 𝑃𝐸 =

$%&'() +, -+.+$/(0 ,+)&(1
$%&'() +, -(..0 0((1(1

𝑥 100%.

The surviving fraction (SF) in each experimental condition was then calculated with
the following equation: 𝑆𝐹 =

$%&'() +, -+.+$/(0 ,+)&(1 8,9() 9)(89&($9
$%&'() +, -(..0 0((1(1 : ;<

𝑥 100%.

Survival curves were generated using the linear quadratic equation: 𝑆(𝐷) =
E

𝑒 ABCADC , where S is the number of surviving cells at dose D. a and b describe the
linear and quadratic components of the curve, respectively, with the ratio of a/b
representing the radiation dose where the cells killed by the linear component is equal
to cell killing by the quadratic component [32]. Curves were compared and graphed
on GraphPad Prism.

Cytotoxicity Assay
Cells were seeded in a 96 well plate at 10,000 cells/mL (200 uL per well,
2,000 cells per well) and allowed to adhere overnight. Cells were then treated with
serial dilutions of AZD6738. After 72 hours of treatment, cultures were fixed with
100uL of 20% trichloroacetic acid (TCA) on top of the culture medium to produce a
final concentration of 10%. The cells were incubated at 4 degrees Celsius
overnight .The plates were washed with tap water and the plate was allowed to
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completely dry before adding 50 uL of 0.4% SRB dissolved in 1% acetic acid to each
well and stained for 10 minutes at room temperature. Unbound dye was removed by 4
washes with 1% acetic acid, and the plate was allowed to dry completely. Proteinbound dye was dissolved with 100 uL of 10mM unbuffered Tris base solution (pH
10.5) for 5 minutes. The plate was read on a microplate reader, and the OD was
measured at 510 nm. Cell growth was expressed as a percentage, defined as the ratio
of the absorbance measured in the treated wells compared with the control well.
Dose-effect curves were generated using Prism.

Immunofluorescence analysis
Cells were seeded on glass cover slips at seeding concentrations of 150,000
cells/mL and allowed to adhere overnight. Cells underwent radiation treatment at a
dose of 5Gy and fixed with 4% formaldehyde at different time points after radiation
(30 min, 1h, 4h, 8h, 24h). Samples were washed with 0.1% triton in PBS and blocked
in 10% normal goat serum in PBS. The samples were then incubated with primary
antibody (1:500, anti-phospho histone gH2AX Ser139, Cell Signaling) at 4 degrees
overnight followed by the secondary antibody (1:750, Alexa Fluor 488-conjugated
goat anti-rabbit IgG, Invitrogen) for 1 hour at room temperature. Samples were
mounted on slides with vectashield mounting solution containing DAPI (Vector
Labs). Images were captured with an inverted Zeiss LSM 510 Pascal laser confocal
microscope. Images were analyzed using ImageJ.

Cell cycle analysis
Cells were seeded in 60mm plates and allowed to adhere overnight. Plates
were irradiated at 5 Gy and fixed with ice-cold 70% ethanol at different time points
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following radiation (0, 1, 2, 8, 24 hrs). Samples were stored overnight at -20 degrees
Celsius. Samples were washed with PBS twice and then incubated with 200 uL of
Guava Cell Cycle Reagant (Guava Technologies) for 30 minutes in the dark.
Cytofluorometric acquisitions were performed with an LSRII cytometer (BD
Biosciences). About 50,000 events were analyzed per condition. Results were
analyzed using FlowJo software.

Western blot
SDS lysate preparation
Cells were cultured on 60mm plates and irradiated at a dose of 5 Gy. Lysates
were harvested from the cultures at several time points after radiation (0, 1, 4, 8, 24
hrs) using boiling SDS lysis buffer (1% SDS, 10 mM Tris-Cl pH 7.5). 250 uL of lysis
buffer were added to the plate and lysates were scraped into Eppendorf tubes. The
lysates were then boiled at 5 minutes and then homogenized by passing through a 26
G needle 6-7 times. The lysates were centrifuged at 12,000 rpm for 5 minutes, and the
supernatant was transferred to a clean tube. Protein concentration was determined
using the DC Protein Assay Kit (Bio-Rad). 4x sample loading buffer was added to the
samples before storing at -20 degrees Celsius.
Gel electrophoresis, transfer, and antibody incubation
40 ug of protein were loaded into wells of a precast gel along with a protein
ladder. The gel was run at 80V for 20 minutes before increasing the voltage to 250 V
to complete the run. Proteins were transferred from the gel to a 0.45 um nitrocellulose
membrane at transfer conditions of 300 mA for 50-60 minutes on ice. The membrane
was then incubated in 5% milk in TBST for 1 hour followed by primary antibody in
5% milk in TBST (rabbit GAPDH 1:5000, Cell Signaling; rabbit ARID1A 1:2000,
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Sigma-Aldrich, rabbit gH2ax 1:2000, Cell Signaling) overnight at 4 degrees Celsius.
The membranes were rinsed in TBST 5 times for 5 minutes each and then incubated
in anti-rabbit HRP-conjugated secondary antibody in 5% milk in TBST at 1:2000
dilution at room temperature for 1 hour. After rinsing the membranes 5 times for 5
minutes each, Pierceä ECL Western Blotting Substrates (Thermo Scientific) were
pipetted onto the membranes. Blots were captured using the CCD imaging system,
and images were analyzed using Image J.

Results
ARID1A-deficient cells exhibit greater sensitivity to radiation treatment
Our first aim was to investigate the effects of ARID1A deficiency on
sensitivity to ionizing radiation. We performed clonogenic survival assays to test the
ability of ARID1A-/- and ARID1A+/+ cells to survive and form colonies after treatment
with radiation. Cells were treated at various doses (1 Gy, 2 Gy, 4 Gy, and 6 Gy) and
allowed to incubate for 10-14 days before colonies were stained and counted. In the
ES2 ovarian clear cell carcinoma cell line, the ARID1A-/- cells compared to
ARID1A+/+ had a decreased surviving fraction of colonies at each administered dose
(Figure 1A). This same result was seen in the HCT116 colorectal cancer cell line. The
survival fraction at 2Gy was decreased from 87% to 41% in ES2 cells and from 54%
to 25% for HCT116 in ARID1A+/+ and ARID1A-/-, respectively (Figure 1B). The
difference in survival was statistically significant at each dose for both cell lines
(denoted by * on the curves). These findings demonstrate that ARID1A deficiency
confers sensitivity to ionizing radiation.
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Figure 1: ARID1A KO cells are more radiosensitive compared to ARID1A WT cells
B

A
ES2
ARID1A+/+

ARID1A-/-

*

*

HCT116
ARID1A+/+

*

ARID1A-/-

0 Gy
1 Gy
2 Gy
*

4 Gy

*
*

*

6 Gy

Figure 1: ARID1A-/- cells are more radiosensitive compared to ARID1A+/+ cells. A Clonogenic
assays in ES2 and HCT116 cell lines after 0, 1, 2, 4, and 6 Gy of radiation. Images are representative of
three independent experiments. B Survival curves for clonogenic assays generated using linear quadratic
equations. Data shown represents mean ± SD, P < 0.05.

ARID1A-deficient cells demonstrate impaired DNA damage response after radiation
Next, we sought to gain more mechanistic insight into the radiosensitivity
exhibited by ARID1A-/- cells. We were interested in investigating the differences in
DNA damage response brought on by ARID1A status following ionizing radiation.
We utilized g-H2AX assays to observe the initial DNA damage response, as the
formation of g-H2AX is an early cellular response to DNA DSBs. First, we examined
g-H2AX foci formation using an immunofluorescence-based assay. Cells were treated
with 5 Gy of radiation, fixed at various time points following radiation treatment, and
incubated with g-H2AX primary antibody. In ES2 ARID1A+/+ cells, we observed
strong induction of g-H2AX foci formation at 1 hour and 4 hours after radiation.
However, ARID1A-/- exhibited reduced g-H2AX foci formation at 1h and 4 hours
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compared to the corresponding time points in ARID1A+/+ cells, suggesting an
impaired DNA damage response (Figure 2A). The same experiment performed in
HCT116 cells demonstrated similar reduction in g-H2AX foci formation in ARID1A-/cells (Figure 3A). Of note, there was some quantitative variability of g-H2AX foci
between replicates, though each replicate consistently demonstrated relative reduction
of g-H2AX foci formation in the ARID1A-/- condition. A representative
immunofluorescence pattern is displayed for ES2 and HCT116 cells in Figures 2A
and 3A, respectively.
To further validate reduced g-H2AX expression in ARID1A-/- cells after
radiation, we measured g-H2AX expression by Western blot in radiation-treated cell
ES2 ARID1A+/+

A
0 Gy

5 Gy, 1h

5 Gy, 4h

ES2 ARID1A-/5 Gy, 24h

0 Gy

5 Gy, 1h

5 Gy, 4h

5 Gy, 24h

DAPI

gH2AX

Merge

B

Figure 2: ARID1A-/- ES2 cells have diminished g-H2AX foci formation following radiation. A
Confocal microscopic images of immunofluorescence of g-H2AX (green) with nuclear stain DAPI (blue).
Images shown are representative of three independent replicates. B Percentage of cells with >15 g-H2AX
foci. Data shown represents mean ± SD.
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HCT116 ARID1A+/+

A
0 Gy

5 Gy, 1h

5 Gy, 4h

HCT116 ARID1A-/5 Gy, 24h

0 Gy

5 Gy, 1h

5 Gy, 4h

5 Gy, 24h

DAPI

gH2AX

Merge

B

Figure 3: ARID1A-/- HCT116 cells have diminished g-H2AX foci formation following radiation on
immunofluorescence. A Confocal microscopic images of immunofluorescence of g-H2AX (green) with
nuclear stain DAPI (blue). Images shown are representative of three independent replicates. B Percentage
of cells with >15 g-H2AX foci. Data shown represents mean ± SD.

lysates at various timepoints following radiation. As demonstrated in Figure 4A,
strong g-H2AX expression was induced in ES2 ARID1A+/+ lysates at 30 minutes after
radiation with increased expression maintained through 4 hours after radiation.
ARID1A-/- lysates demonstrated some induction of g-H2AX expression at 30 minutes
and 1 hour after radiation, though expression is reduced compared to the
corresponding time point in ARID1A+/+ lysates. Similar results are observed in
HCT116 lysates as demonstrated in Figure 4B. All together, these results suggest that
ARID1A deficiency likely generates an impaired initiation of the DNA damage
response.
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Figure 4: ARID1A-/- cells have diminished g-H2AX expression following radiation by Western blot
analysis. A Western blot showing changes in g-H2AX expression at various time points following 5Gy of
radiation in ES2 ARID1A+/+ and ARID1A-/- cell lysates. B Western blot showing changes in g-H2AX
expression in HCT116 cell lysates.

Next, in order to further investigate the DNA damage response after radiation,
we examined the expression of CHK1, a protein kinase that is involved in the DNA
damage response and cell cycle checkpoint response. Phosphorylation of CHK1 (pCHK1) is required for activation. We performed a Western blot looking at total
CHK1 and p-CHK1 expression in HCT116 cell lysates at various time points after 5
Gy of radiation (Figure 5). Total CHK1 expression was consistent between
ARID1A+/+ and ARID1A-/- lysates. With regards to p-CHK1, ARID1A+/+ lysates
demonstrated peak p-CHK1 expression at 1 hour after radiation with slight decreases
in expression through 24 hours. ARID1A-/- lysates had a delayed peak p-CHK1
expression at 4-8 hours and additionally and diminished p-CHK1 expression at every
time point compared to ARID1A+/+ lysates. Of note, ARID1A-/- lysates did appear to
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have decreased baseline p-CHK1, as demonstrated by the very faint band at 0 Gy.
Thus, it may be difficult to definitively comment about quantitative differences in pCHK1 expression. Nevertheless, the delayed peak of p-CHK1 in ARID1A-/- cells
further demonstrates that ARID1A deficiency confers an impairment in the DNA
damage response cascade.

Figure 5: ARID1A-/- cells have delayed p-CHK1 expression following radiation by Western blot
analysis. AWestern blot showing changes in total CHK1 and p-CHK1 expression at various time points
following 5Gy of radiation in HCT116 ARID1A+/+ and ARID1A-/- cell lysates.

ARID1A-deficient cells exhibit impaired G2/M cell cycle checkpoint following
radiation
Given our finding of a delay in p-CHK1 expression within ARID1A-.- cells and
the role of CHK1 in cell cycle checkpoint activation, we next wished to investigate
the cell cycle distribution at various time points following radiation treatment.
Radiation-treated HCT116 cells were fixed at the desired time points, stained with
nuclear DNA stain propidium iodide, and quantitation was performed by flow
cytometry. As shown in Figure 6, accumulation of cells at the G2/M checkpoint was
observed in ARID1A+/+ cells after 30 min and 1 hour after radiation, demonstrating an
appropriate G2/M cell cycle arrest after radiation-induced damage. However, within
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ARID1A-/- cells, accumulation at the G2/M checkpoint did not occur in until 8 hours
after radiation, demonstrating that ARID1A-/- cells have a delayed G2/M cell cycle
arrest in response to radiation compared to ARID1A+/+ cells. This result corresponds
well with our previous finding of a delayed p-CHK1 peak expression at 8 hours, as
the presence of activated CHK1 is an important signal transducer for the G2/M
checkpoint activation.

Figure 6: ARID1A-/- cells demonstrate impaired G2/M cell cycle checkpoint. A Histograms showing
DNA content determined by flow cytometry in HCT116 ARID1A+/+ and ARID1A-/- cell lines. B Graph
demonstrating the fold change of cells at G2/M checkpoint.

ARID1A-knockout cells demonstrate sensitization to ATR blockade alone
Previous work has identified ARID1A deficiency as a biomarker for sensitivity
to clinical ATR inhibitors, such as AZD6738. We hoped to validate this phenomenon
in our ES2 ovarian clear cell carcinoma cell line model and thus investigated the
effects of AZD6738 on the survival of ARID1A-/- cells through cytotoxocity assays.
Cells were treated with serial dilutions of AZD6738 for 72 hours, and cell survival
was measured using an SRB assay. As demonstrated in Figures 6A and 6B, ARID1A-/ES2 cells were significantly more sensitive to AZD6738 compared to ARID1A+/+ ES2
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cells. Similar results were observed in isogenic paired HCT116 cell lines (Figures 7C
and 7D).

Figure 7: ARID1A-/- cells demonstrate sensitization to ATR blockade. A Relative cell survival shown
following AZD6738 treatment at various concentrations for 72 hours in ES2 ARID1A-/- cells (blue/green)
and ARID1A+/+ cells (black/gray). B Graph demonstrating the AZD6738 concentration resulting in 50%
growth inhibitory effect (IC50) in ES2 cells. C Relative cell survival following AZD6738 treatment at
various concentrations for 72 hours in HCT116 ARID1A-/- cells (blue) and ARID1A+/+ cells (pink). D
Graph demonstrating the AZD6738 concentration resulting in 50% inhibitory effect in HCT116 cells.

ARID1A-deficient cells may be more sensitive to AZD6738 treatment prior to
radiation compared to radiation alone
As detailed above, ARID1A-/- cells were nevertheless able to proceed with a
DNA damage response albeit in a delayed fashion, exhibited by a delayed increase in
p-CHK1 expression and delayed cell cycle arrest. This raised the possibility that the
cell cycle checkpoint may be a potential target for a synthetic lethal agent. In
particular, we were interested in the possibility that ATR blockade could target the
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potential increased reliance on ATR checkpoint activity in ARID1A-/- cells treated
with radiation. In order to investigate if ATR blockade may further sensitize
ARID1A-/- cells to radiation, we tested the combination treatment of AZD6738 with
radiation on clonogenic survival in HCT116 isogenic paired cell lines. Cells were
treated with AZD6738 1 hour prior to radiation treatment and medium was removed
24 hours after radiation. As expected, ARID1A-/- cells were more radiosensitive
compared to ARID1A+/+ cells. ATR blockade appeared to slightly sensitize ARID1A/-

cells to radiation compared to radiation alone, though the difference was only

significant at the 6 Gy dose of radiation (Figure 8).

Figure 8: ATR blockade may further sensitize ARID1A-/- cells to radiation. A Clonogenic survival
assay of HCT116 cells after 0, 1, 2, 4, and 6 Gy of radiation with and without AZD6738 treatment 1 hour
prior to radiation. Images representative of 3 independent replicates. B Survival curves for clonogenic
assays generated using linear quadratic equations. Data shown represents mean ± SD, P < 0.05.
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Discussion
ARID1A is a frequently mutated gene, especially amongst gynecologic
malignancies, particularly ovarian and endometrial cancers. In this work, we
investigated ARID1A deficiency as a biomarker for treatment sensitivity to radiation
therapy, ATR blockade, and combination treatment of ATR blockade prior to
radiation treatment. We use cell line models of ovarian clear cell carcinoma (ES2) and
colorectal carcinoma (HCT116). We found that ARID1A-deficient cells were more
sensitive to radiation treatment as shown by decreased clonogenic survival among the
ARID1A-/- cells. In examining the DNA damage response of ARID1A-deficient cells
after radiation therapy, we found that ARID1A-/- cells have diminished gamma-H2AX
foci formation, delayed p-CHK1 expression, and delayed cell cycle arrest at G2/M. In
addition, our results confirm that ARID1A-/- cells exhibit increased sensitivity to ATR
inhibitor AZD6738 in an ovarian clear cell carcinoma model. Our clonogenic assays
investigating cell sensitivity to ATR blockade prior to radiation treatment
demonstrated slightly increased sensitivity in ARID1A-/- cells compared to ARID1A+/+
cells, though this difference was not significant. Collectively, we believe this work
provides valuable insight into how mechanistic weaknesses produced by ARID1A
deficiency can be used to investigated more targeted therapies for ARID1A-mutant
cancers.
As ARID1A has been shown to have many tumor suppressor roles, therapeutic
strategies targeting ARID1A are more challenging compared to proto-oncogenes.
Many strategies rely on the principle of synthetic lethality, the most famous example
of which is the use of PARP inhibitors in BRCA-mutant cancers, in which inhibition
of PARP’s single-stranded DNA repair ultimately leads to DNA DSBs that are unable
to be repaired in BRCA-mutant cells [33]. ARID1A’s tumor suppressing roles within
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maintaining genome integrity is the most relevant to our work, as we hoped to
investigate the DNA damage response and repair vulnerabilities engendered by
ARID1A deficiency and how these may be sensitize ARID1A-mutant tumors to
radiation and ATR blockade.

ARID1A deficiency as a biomarker for radiation sensitivity
Based on previous work demonstrating defective DSB repair in ARID1Adeficient cells, we hypothesized that ARID1A-deficient cells would be sensitized to
radiation-induced DNA damage.
Our first set of experiments centered around the clonogenic survival assay, a
cell culture technique to evaluate the ability of a cell to grow into a colony through
unlimited division. The clonogenic survival assay is the technique of choice to
investigate cell reproductive death after radiation treatment, though can also be used
to evaluate other agents as well [34]. We used this assay to assess the radiosensitivity
of ARID1A-/- cells compared to ARID1A+/+ cells. Treatment conditions included
radiation at 0 Gy, 1 Gy, 2 Gy, 4 Gy, and 6 Gy. ARID1A-/- cells had a diminished
surviving fraction at each dose of radiation compared to ARID1A+/+ cells, and the
difference between these curves was statistically significant. We saw this result in
both ES2 and HCT116 cell lines, demonstrating that ARID1A-deficient cells are more
sensitive to ionizing radiation compared to ARID1A-intact cells in a colorectal and
ovarian clear cell carcinoma cell line model. The clinical implication of this finding is
the potential ability to use ARID1A mutations as a biomarker for treatment sensitivity
to radiotherapy.
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Clinical considerations for radiation therapy in ARID1A-mutant cancers
ARID1A mutations have high specificity for certain histologic subtypes within
ovarian and endometrial cancers, with the highest frequency occurring in ovarian
clear cell, ovarian endometrioid, and uterine endometrioid adenocarcinomas. The role
of radiotherapy in uterine cancer is much more well-defined than in ovarian cancer,
with adjuvant radiotherapy in endometrial cancer employed based on risk
stratification groups based on clinicopathologic factors and recently, molecular
characteristics, as seen in new European guidelines [35, 36]. However, ARID1A
mutations are not among the molecular factors currently considered in the European
guidelines. Much further work elucidating the prognostic value of ARID1A mutations
within endometrial cancers would be needed before placing further deliberation into
how this molecular consideration could be used to influence choices for adjuvant and
novel therapies.
With regards to ovarian cancer, radiotherapy is more rarely used in adjuvant
treatment. Because ovarian cancer has a tendency to disseminate via transperitoneal
spread, cancer often spreads beyond the pelvis, rendering radiotherapy a less effective
strategy for disease control. While whole abdominal radiotherapy was utilized for
ovarian cancer prior to the cisplatin era, the lower doses required to protect the organs
at risk usually resulted in poor therapeutic efficacy [37]. Thus, the mainstay of
adjuvant treatment for ovarian cancer has remained platinum-based regimens for
several decades, and radiotherapy is instead utilized only in some patients with
refractory and resistant disease. However, more advanced radiotherapy techniques
have vastly improved the potential for radiotherapy use in metastatic diseases and has
inspired renewed interest in using radiotherapy for ovarian cancer. For example, in
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intensity-modulated radiotherapy (IMRT), beams can be shaped and modulated,
allowing for a more optimized dose to the target while minimizing dose to
surrounding organs at risk [37]. A phase II trial (OVAR-IMRT-02) assessing whole
abdominal IMRT after cytoreductive surgery and chemotherapy in 20 high risk
ovarian cancer patients found acceptable toxicities and promising recurrence-free and
overall survival [38]. This highlights future potential for IMRT as a more targeted
means to treat ovarian cancer. Additional considerations for radiotherapy for the
treatment of ovarian cancer include the potential for low-dose fractionated whole
abdominal radiotherapy to be a sensitizer for chemotherapy agents, such as
antimetabolite drugs that inhibit DNA synthesis or agents disrupting DNA repair.
Additionally, the abscopal effects of radiotherapy, in which radiation leads to the
release of tumor antigens and activation of immune response, is an increasing area of
interest in exploring the synergy between radiation and immunotherapy.
Over 50% of clear cell ovarian cancers have ARID1A mutations, making our
work to elucidate targeted therapies for ARID1A-mutant cancers especially relevant
for this subtype. The clear cell subtype is known to exhibit poorer sensitivity to
chemotherapy regimens compared to the more common serous subtype. While earlystage clear cell patients tend to have a better prognosis than their serous counterparts,
advanced stage clear cell patients appear to have a poorer prognosis [39]. Given the
paucity of data for the clear cell subtype, treatment is largely extrapolated from
epithelial ovarian cancer trials, in which clear cell patients make up only a small
percentage of subjects [40]. Thus, the optimal management of ovarian clear cell
carcinoma remains unclear. Further, the relative resistance of the clear cell subtype to
chemotherapeutic agents has raised interest in identifying other therapies that may be
effective, including radiotherapy [39], particularly since the first site of recurrence for
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many of these patients is in the pelvis. In a study of 241 patients with early stage
ovarian clear cell patients, the addition of radiotherapy to chemotherapy significantly
improved recurrence-free survival only in stage IC2/3 and II, but not in stage IA/B or
IC1 [41]. In another retrospective study of 163 early-stage ovarian clear cell patients,
adjuvant radiotherapy was not found to be associated with improved recurrence-free
or overall survival, though this study did not include information about or stratify
outcomes by ARID1A status [42] and thus may not have isolated the specific subset of
patients who potentially may benefit from adjuvant radiotherapy. Given the results of
our study, it would appear that ARID1A deficiency is a potential biomarker
identifying clear cell carcinoma patients who may benefit from radiotherapy, and
further work investigating the clinical implications of ARID1A deficiency among
clear cell patients is warranted. This more sophisticated understanding of molecular
biomarkers in combination with more advanced radiotherapy techniques can be
utilized in the future to optimize adjuvant treatment for this patient population.
Further work investigating advanced radiation techniques within the ARID1Adeficient clear cell ovarian carcinoma population would be needed to gather clinical
data on this hypothesis.

DNA damage response in ARID1A-deficient cells
Our additional aim was to investigate the DNA damage response in ARID1A-/cells in efforts to explore mechanisms of radiosensitivity and to explore other
potential therapeutic vulnerabilities in ARID1A-/- cells following radiation. We used gH2AX assays as one way to observe the initial DNA damage response. The histone
variant H2AX is phosphorylated at the Ser-139 residue by kinases in the PI3 family,
including ATR and ATM, forming g-H2AX [43]. Formation of g-H2AX is an early
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cellular response to DNA DSBs and thus can be used as a marker for the DNA
damage response initiation. An expected response to ionizing radiation would be
increased g-H2AX foci formation. In our study, we observed g-H2AX nuclear foci
formation by an immunofluorescence-based assay and found that after 5 Gy of
radiation, ARID1A-/- cells exhibited diminished g-H2AX foci formation compared to
ARID1A+/+ counterparts at each time point. While this observation of relative
diminishment of g-H2AX foci formation in ARID1A-/- was consistent across
independent replicate experiments, there remained quantitative differences between
replicates. For example, one replicate may have had quantitively higher g-H2AX
expression across all groups compared to another replicate; however, the ARID1A-/group still consistently demonstrated relatively decreased foci formation compared to
the ARID1A+/+ within the same replicate. Because of this, the difference in g-H2AX
foci formation did not reach statistical significance. Additional replicates of this
experiment may be needed in addition to further troubleshooting of this experimental
technique to standardize immunofluorescent staining. We also tested the expression of
g-H2AX by Western blot in cell lysates after 5 Gy radiation, which similarly
demonstrated decreased expression of g-H2AX in ARID1A-/- lysates compared to
ARID1A+/+ lysates, most notably at 1 hour after radiation. Our finding that ARID1A-/cells have diminished g-H2AX expression following radiation-induced DNA damage
suggests that the radiosensitivity exhibited by ARID1A-/- cells may in part be due to
impaired DNA damage detection and response.
We additionally measured the expression of p-CHK1 at various time points
after radiation. CHK1 is a protein kinase that plays an important role in coordinating
the DNA damage response and is required for the activation of DNA damage
checkpoints during the cell cycle. CHK1 is activated upon phosphorylation by ATR
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[44]. We found that ARID1A-/- cells exhibited delayed peak expression of p-CHK1,
and this finding was further evidence that ARID1A deficiency conferred an
impairment in the DNA damage response. Further, given the role of CHK1 in cell
cycle checkpoint activation, we performed cell cycle experiments to evaluate the
impact that ARID1A deficiency may have on the cell cycle after radiation. Our data
demonstrates that while ARID1A+/+ cells exhibited G2/M arrest at 1 hour, ARID1A-/cells did not exhibit G2/M arrest until the 8 hour mark, aligning with the delayed pCHK1 peak expression. Thus, ARID1A-/- cells have aberrations in cell cycle arrest
following radiation-induced DNA damage. Failure to arrest at G2 hinders the cell’s
subsequent ability to repair the DNA damage [45] and may contribute to the
radiosensitivity of ARID1A-/- cells. However, we did observe ARID1A-/- cells were
still able to achieve cell cycle arrest albeit in a delayed manner and perhaps retain
some vestige ability to undergo DNA repair prior to entering mitosis. This presents a
potential vulnerability that may be targeted with additional agents that may further
disrupt cell cycle checkpoint activation, such as ATR inhibitors.

ATR inhibitors in ARID1A deficiency
ATR inhibitors have previously been investigated in ARID1A deficiency, with
ARID1A-deficient cell lines exhibiting increased sensitivity to single-agent ATR
inhibitors [27]. In this work, Williamson et al. present a working model for the
synthetic lethality of ARID1A and ATR, in which loss of ARID1A results in defective
recruitment of DNA topoisomerase TOP2A to chromatin, resulting in a DNA
decatenation defect. This defect in the ability to modify the topological structure of
DNA is likely to disrupt vital cell activities, such as DNA replication and
transcription. The failure to ultimately resolve these issues would thus cause genomic
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instability and an increased reliance on ATR checkpoint activity that can be targeted
with ATR inhibitors. They found that ARID1A deficiency sensitized cells to ATR
blockade, which triggered premature mitotic entry and ultimately cell death. Of note,
this important study conducts experiments within a colorectal cancer cell line model.
Thus, we validated these results in a ovarian clear cell carcinoma cell line model and
confirmed the increased sensitivity of the ARID1A-/- cells to the ATR inhibitor
AZD6738 compared to ARID1A+/+ cells.
Clinical ATR inhibitors have been explored in clinical trials in recent years,
primarily in advanced solid tumors and in combination with other chemotherapeutic
agents, most of which are ongoing [46-51]. One phase I trial with 52 patients who
received ATR inhibitor VX-970 in combination with gemcitabine for
resistant/refractory advanced solid tumors demonstrated that this treatment regimen
was well-tolerated in patients and showed preliminary efficacy [52]. Specifically in
ARID1A-mutant gynecologic cancers, there is a current phase II clinical trial
investigating ATR inhibitors in combination with PARP inhibitors in patients with
ARID1A-mutant cancers [53]. This proof-of-concept trial will be very useful in
revealing the feasibility and efficacy of using ATR inhibitors in treatment of ARID1Amutant gynecologic cancers.
As mentioned above, previous work has shown that ATR inhibition in
ARID1A-deficient tumors causes premature mitotic entry [27]. Further, our data
suggests that ARID1A-/- cells treated with radiation may have a delayed cell cycle
arrest. We hypothesized that ATR blockade would further sensitize ARID1A-/- cells to
radiation therapy, with the thought that the radiation-induced delayed cell cycle arrest
in ARID1A-/- cells would force increased reliance on ATR checkpoint activity. In our
clonogenic survival assay, we treated cells with AZD6738 1 hour prior to radiation
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treatment and replaced the drug-containing medium with fresh medium after 24
hours. With these conditions, though there was slight sensitivity of ARID1A-/- to the
combination treatment compared to radiation alone, the difference was only
significant at 6 Gy of radiation. Of note, however, is that our data demonstrating
increased sensitivity to ATR blockade in ARID1A-/- cells was after 72 hours of
AZD6738 treatment. Thus, it is possible that a longer treatment period with ATR
inhibitor before or after radiation treatment may be necessary to observe a significant
effect in ARID1A-/- cells. Future experiments will explore timing of ATR blockade
prior to radiation, as well as the duration of drug treatment (with re-dosing as needed)
after radiation treatment to more thoroughly evaluate this combination treatment in
the setting of ARID1A deficiency.

Limitations and future directions
Much more future work is warranted with regards to investigating ARID1A
deficiency. We hope to continue gaining mechanistic insight into ARID1A
deficiency’s impact on the DNA damage response to explore potential vulnerabilities
and to shed light on future targeted therapies for ARID1A-mutant tumors. Specifically,
we believe that further insight into how ARID1A deficiency impacts specific DNA
repair pathways may reveal further synthetic lethal targets.
A limitation of this work is the use only of in vitro cell line models. Future
experiments will seek to validate results in patient-derived models with ARID1A
mutations, rather than cell lines with experimental gene knockouts. Further, we will
validate radiation and ATR blockade sensitivity within in vivo mice models in
addition to using patient-derived xenografts. In the clinical setting, further work is
needed to discern the prognostic value of ARID1A deficiency in gynecologic
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malignancies to identify populations who may benefit from novel adjuvant therapies,
particularly among ARID1A-mutant uterine cancer populations. Among ARID1Amutant ovarian clear cell carcinoma patients, who tend to be more resistant to current
chemotherapeutic regimens, future clinical trials testing the efficacy of treatments that
may be more sensitive in ARID1A-mutant tumors are warranted. Though radiotherapy
is not commonly used in ovarian cancer currently, advancements in radiation
techniques has generated renewed interest in the application of radiotherapy in
ovarian cancer and should be considered in the setting of ARID1A deficiency.
We hope that our work has contributed to the literature exploring ARID1A
deficiency. In an age of medicine in which a greater understanding of cancer
genomics informs targeted therapeutics, we hope our work brings us closer to finding
optimized therapies for patients with ARID1A-mutant malignancies.

Comments about the COVID-19 era
This work was completed during the time period of September 2020 – July
2021 during the COVID-19 era, which posed considerable challenges on this project.
As a new laboratory trainee, I had much to learn by way of laboratory protocols, cell
culture, equipment use, and experimental techniques. Given social distancing
requirements, I was unable to work closely with mentors and senior members of the
lab and instead learned from distanced instruction and/or independent study. In
addition, I had to troubleshoot day-to-day experiments more independently without
the immediate presence of more senior members and had to be more proactive with
seeking assistance. Nevertheless, I am incredibly grateful to have had this opportunity
to work on this fascinating project and continue to foster my lifelong interest in
cancer genetics. I do believe that this time period has strengthened my ability to think
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and learn more independently, to be proactive in seeking assistance, and to maintain
optimism in the face of unforeseen challenges, all of which I believe are valuable
skills for me, as I look forward to my aspirations of becoming a physician-scientist.
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